Strs Ohio Grows Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Strs Ohio grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,960 shares of the medical research company’s stock after buying an additional 1,363 shares during the quarter. Strs Ohio owned 0.07% of Charles River Laboratories International worth $8,264,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Private Advisor Group LLC lifted its stake in Charles River Laboratories International by 15.4% during the first quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after purchasing an additional 178 shares during the last quarter. Panagora Asset Management Inc. lifted its position in Charles River Laboratories International by 236.5% in the 1st quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock worth $773,000 after buying an additional 1,913 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Charles River Laboratories International by 6.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock worth $1,917,000 after buying an additional 418 shares in the last quarter. Great West Life Assurance Co. Can grew its position in Charles River Laboratories International by 0.4% during the first quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock valued at $7,465,000 after acquiring an additional 107 shares during the last quarter. Finally, Raymond James Trust N.A. raised its stake in shares of Charles River Laboratories International by 33.7% during the first quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after acquiring an additional 384 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. UBS Group increased their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Citigroup boosted their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Argus raised their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 in the last three months. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $229.90 on Thursday. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a 50-day simple moving average of $253.47 and a two-hundred day simple moving average of $220.92. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The firm has a market capitalization of $11.84 billion, a PE ratio of 24.96, a price-to-earnings-growth ratio of 1.85 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.98 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).